DIOSYNVAX
DIOSyn Vax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) is new technology that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.
DIOSYNVAX
Industry:
Biotechnology Information Technology
Founded:
2017-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.diosvax.com
Total Employee:
11+
Status:
Active
Total Funding:
46.47 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail GStatic Google Static Content Google Cloud
Similar Organizations
ENOUGH
ENOUGH is a foodtech startup producing protein through fermenting fungi using renewable feedstocks.
Sano Genetics
Sano Genetics is a personalised medicine research platform with data privacy and transparency at its core.
inveox
Automating histopathology, making cancer diagnoses faster, safer and more reliable.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Rebecca Kinsley Chief Operating Officer @ DIOSynVax
Chief Operating Officer
2019-06-01
Jonathan Heeney CEO @ DIOSynVax
CEO
2017-07-01
Investors List
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations investment in Grant - DIOSynVax
Innovate UK
Innovate UK investment in Grant - DIOSynVax
Parkwalk Advisors
Parkwalk Advisors investment in Seed Round - DIOSynVax
Official Site Inspections
http://www.diosvax.com
- Host name: 185-151-30-121.ptr4.stackcp.net
- IP address: 185.151.30.121
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "DIOSynVax"
DIOSynVax - Crunchbase Company Profile & Funding
Contact Email enquiries@diosvax.com DIOSyn Vax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) is new technology that will …See details»
DIOSynVax - LinkedIn
DIOSVax is a biotech startup working to revolutionise the way humanity protects itself from infectious disease and emerging pathogens. The company is named after its core technology, DIOSynVax ...See details»
DIOSynVax Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for DIOSynVax. Use …See details»
DIOSynVax - Devex
Devex is the media platform for the global development community. A social enterprise, we …See details»
Cambridge coronavirus vaccine enters clinical trial
Dec 14, 2021 While most COVID-19 vaccines use the sequence of the RNA for the virus spike protein from the first isolated samples of the COVID-19 virus in January 2020, this new DIOSvax technology uses predictive methods to …See details»
Pioneering needle-free Covid vaccine begins trials | CUH
Apr 24, 2023 While most Covid vaccines use the Spike protein sequence encoded by the RNA of the sequences from a Wuhan Covid patient reported in January 2020, this new DIOSvax technology uses computational and protein …See details»
Cambridge-developed SARS-CoV-2 vaccine receives £1.9million …
Aug 26, 2020 Innovate UK, the UK government’s innovation agency, has provided the funding …See details»
DIOSynVax: tackling COVID-19 – Cambridge Enterprise
Apr 28, 2021 DIOSynVax. Luckily, he had a head start. In 2017, he had founded spin-out …See details»
DIOSynVax works towards COVID-19 vaccine - Cambridge Enterprise
Mar 17, 2020 The World Health Organization has officially declared the outbreak a pandemic. …See details»
DIOSynVax | EU-Startups
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can …See details»
Needle phobia covid vaccine: Cambridge scientist helps create …
Dec 14, 2021 A University of Cambridge scientist helped develop the new DIOSvax needle …See details»
cambridge needle free covid vaccine trial | University of …
Dec 14, 2021 While most COVID-19 vaccines use the sequence of the RNA for the virus …See details»
Cambridge needle-free coronavirus vaccine enters clinical trial
Dec 14, 2021 Developed by Professor Jonathan Heeney at the University of Cambridge and …See details»
Needle-free Covid-19 vaccine being trialled in the UK
Dec 14, 2021 The new DIOSvax needle-free vaccine being trialled at the University of …See details»
Covid: Jab-free vaccine targeting new variants to be trialled
Dec 14, 2021 While most existing Covid-19 vaccines use the sequence of the RNA for the …See details»
First needle-less Covid vaccine that could work against all variants ...
Dec 14, 2021 Named DIOSvax, the vaccine is made with DNA and is designed to work on all …See details»
Covid-19: Cambridge vaccine aims to 'take care of' variants
Feb 1, 2021 A coronavirus vaccine being developed in Cambridge will aim to "take care of" …See details»
Southampton trial needle-free vaccine for COVID-19 variants and …
Dec 14, 2021 Southampton has launched a trial for a pioneering vaccine technology that …See details»
Trial Begins for Needle-Free COVID Vaccine - Medscape UK
Dec 15, 2021 The vaccine candidate is based on the University of Cambridge's DIOSvax …See details»
WHO DIOSynVax Pan-Sarbeco Vaccines 280122
Www.diosvax.com. Title: WHO DIOSynVax_Pan-Sarbeco Vaccines 280122 Author: Jonathan …See details»